{"id":"W2947946663","doi":"10.1200/jco.2019.37.15_suppl.5010","title":"Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Western University","funders":"","keywords":"Medicine; Enzalutamide; Abiraterone; Rash; Nausea; Prostate cancer; Cohort; Internal medicine; Cancer; Oncology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009966356,0.0006889333,0.0007710511,0.0002806583,0.0003523373,0.0005247301,0.0004226664,0.0005284645,0.001911475],"category_scores_gemma":[0.0004839289,0.0003442588,0.0006950622,0.0003656955,0.0003440941,0.0004337973,0.0002833466,0.001319405,0.000420998],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008113609,"about_ca_system_score_gemma":0.001227197,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002266248,"about_ca_topic_score_gemma":0.007037976,"domain_scores_codex":[0.9997643,0.00009170064,0.00002076858,0.00003909879,0.00003618958,0.00004799895],"domain_scores_gemma":[0.999652,0.0000374143,0.00007172684,0.00001944537,0.00001798275,0.0002014269],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6955417,0.04720831,0.07274416,0.001219564,0.003036075,0.0005300379,0.0005142695,0.003229449,0.04442711,0.000200949,0.006478541,0.1248699],"study_design_scores_gemma":[0.3459395,0.4648216,0.1715556,0.0001345681,0.001919253,0.0008759288,0.0001747562,0.001372311,0.004963261,0.0001377391,0.008060805,0.00004474094],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9954597,0.001424457,0.0001541824,0.0001405098,0.00002592038,0.0009325699,0.0008876001,0.00001690024,0.0009580913],"genre_scores_gemma":[0.9945154,0.001308362,0.0005222688,0.0003001813,0.00006536205,0.0005556864,0.001697183,0.000006666306,0.001028964],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002266248,"threshold_uncertainty_score":0.006394446,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08409594014976089,"score_gpt":0.4644896020229624,"score_spread":0.3803936618732015,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}